Express Scripts Stock Price, News & Analysis (NASDAQ:ESRX)

$68.57 0.01 (0.01 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$68.56
Today's Range$67.97 - $69.30
52-Week Range$55.80 - $73.42
Volume3.72 million shs
Average Volume4.11 million shs
Market Capitalization$38.83 billion
P/E Ratio10.02
Dividend YieldN/A
Beta0.88

About Express Scripts (NASDAQ:ESRX)

Express Scripts logoExpress Scripts, Inc. is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM). PBM segment’s services include retail network pharmacy management and retail drug card programs, home delivery services, specialty benefit services, patient care contact centers, benefit plan design and consultation, drug formulary management, compliance and therapy management programs, information reporting and analysis programs, rebate programs, and electronic claims processing and drug utilization review. EM segment’s services include distribution of pharmaceuticals and medical supplies to providers and clinics and healthcare account administration and implementation of consumer-directed healthcare solutions.

Receive ESRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Health Care Plans
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:ESRX
CUSIP30219G10
Phone314-996-0900

Debt

Debt-to-Equity Ratio0.86%
Current Ratio0.73%
Quick Ratio0.61%

Price-To-Earnings

Trailing P/E Ratio10.02
Forward P/E Ratio9.78
P/E Growth1.01

Sales & Book Value

Annual Sales$100.29 billion
Price / Sales0.39
Cash Flow$10.04 per share
Price / Cash6.83
Book Value$26.34 per share
Price / Book2.60

Profitability

Trailing EPS$6.07
Net Income$3.40 billion
Net Margins3.64%
Return on Equity25.46%
Return on Assets7.95%

Miscellaneous

Employees25,600
Outstanding Shares566,370,000

Express Scripts (NASDAQ:ESRX) Frequently Asked Questions

What is Express Scripts' stock symbol?

Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."

How were Express Scripts' earnings last quarter?

Express Scripts Holding Company (NASDAQ:ESRX) released its quarterly earnings results on Tuesday, October, 24th. The company reported $1.90 EPS for the quarter, hitting the Zacks' consensus estimate of $1.90. The company had revenue of $24.68 billion for the quarter, compared to analyst estimates of $25.68 billion. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. Express Scripts's revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.74 earnings per share. View Express Scripts' Earnings History.

When will Express Scripts make its next earnings announcement?

Express Scripts is scheduled to release their next quarterly earnings announcement on Tuesday, February, 13th 2018. View Earnings Estimates for Express Scripts.

What guidance has Express Scripts issued on next quarter's earnings?

Express Scripts issued an update on its fourth quarter earnings guidance on Tuesday, October, 24th. The company provided earnings per share (EPS) guidance of $2.03-2.11 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.04.

Where is Express Scripts' stock going? Where will Express Scripts' stock price be in 2017?

21 analysts have issued twelve-month target prices for Express Scripts' shares. Their forecasts range from $57.00 to $87.00. On average, they anticipate Express Scripts' share price to reach $71.83 in the next twelve months. View Analyst Ratings for Express Scripts.

What are Wall Street analysts saying about Express Scripts stock?

Here are some recent quotes from research analysts about Express Scripts stock:

  • 1. According to Zacks Investment Research, "We are upbeat about Express Scripts’ pharmacy-benefits management long-term outlook. The projection takes the volatile healthcare market trends, inflation, patent expiration and lower industry utilization growth into consideration. Furthermore, Express Scripts should benefit from increased generic utilization, shift toward mail orders, strong specialty growth and an aging population. Branded drugs are becoming increasingly expensive due to double-digit brand inflation. Thus, continued rise in the price of specialty drugs and overwhelming regulatory burden is opening up considerable prospects for generics. However, over the past one year, Express Scripts has underperformed the broader industry in terms of price. Tough competition in the niche space and the persistent drug pricing issue are anticipated to affect the stock." (10/24/2017)
  • 2. Jefferies Group LLC analysts commented, "We believe ESRX remains a Buy given our view that company fundamentals, including its FCF, are stable and that the stock's valuation is attractive at 9x FY18 P/E. That said, we recognize that headlines surrounding drug pricing pressure and the overhang from ESRX's Anthem contract will drive continued stock volatility NT." (2/17/2017)

Are investors shorting Express Scripts?

Express Scripts saw a increase in short interest in November. As of November 30th, there was short interest totalling 30,738,576 shares, an increase of 1.3% from the November 15th total of 31,157,833 shares. Based on an average daily volume of 3,982,136 shares, the short-interest ratio is currently 7.7 days. Approximately 5.4% of the company's shares are short sold.

Who are some of Express Scripts' key competitors?

Who owns Express Scripts stock?

Express Scripts' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Barrow Hanley Mewhinney & Strauss LLC (3.30%), Macquarie Group Ltd. (1.99%), Veritas Asset Management LLP (1.50%), Bank of New York Mellon Corp (1.35%), Nordea Investment Management AB (1.29%) and Dimensional Fund Advisors LP (1.16%). Company insiders that own Express Scripts stock include Christopher A Mcginnis, Everett Neville, Mahon Thomas P Mac, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.

Who sold Express Scripts stock? Who is selling Express Scripts stock?

Express Scripts' stock was sold by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, Kensico Capital Management Corp, Bank of New York Mellon Corp, Old Mutual Global Investors UK Ltd., Barrow Hanley Mewhinney & Strauss LLC, Brown Advisory Inc., Macquarie Group Ltd. and Brandes Investment Partners LP. Company insiders that have sold Express Scripts company stock in the last year include Everett Neville, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts.

Who bought Express Scripts stock? Who is buying Express Scripts stock?

Express Scripts' stock was purchased by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Pzena Investment Management LLC, Schwab Charles Investment Management Inc., Stifel Financial Corp, Veritas Asset Management LLP, Russell Investments Group Ltd., Prudential Financial Inc. and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Express Scripts.

How do I buy Express Scripts stock?

Shares of Express Scripts can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Express Scripts' stock price today?

One share of Express Scripts stock can currently be purchased for approximately $68.57.

How big of a company is Express Scripts?

Express Scripts has a market capitalization of $38.83 billion and generates $100.29 billion in revenue each year. The company earns $3.40 billion in net income (profit) each year or $6.07 on an earnings per share basis. Express Scripts employs 25,600 workers across the globe.

How can I contact Express Scripts?

Express Scripts' mailing address is ONE EXPRESS WAY, ST. LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]


MarketBeat Community Rating for Express Scripts (ESRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  665 (Vote Outperform)
Underperform Votes:  447 (Vote Underperform)
Total Votes:  1,112
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Express Scripts (NASDAQ:ESRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.192.092.182.21
Ratings Breakdown: 3 Sell Rating(s)
11 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
12 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
12 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
13 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $72.00$70.46$70.46$75.24
Price Target Upside: 5.00% upside15.21% upside12.16% upside22.51% upside

Express Scripts (NASDAQ:ESRX) Consensus Price Target History

Price Target History for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ:ESRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2017Maxim GroupBoost Price TargetBuy$78.00 -> $87.00LowView Rating Details
12/6/2017Sanford C. BernsteinUpgradeUnderperform -> Market PerformLowView Rating Details
12/4/2017Deutsche BankInitiated CoverageBuy$75.00HighView Rating Details
10/26/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
10/25/2017Royal Bank of CanadaSet Price TargetHold$66.00N/AView Rating Details
10/25/2017Robert W. BairdBoost Price TargetNeutral$57.00 -> $59.00N/AView Rating Details
10/24/2017MizuhoSet Price TargetHold$67.00N/AView Rating Details
10/9/2017Raymond James FinancialReiterated RatingMarket Perform -> UnderperformN/AView Rating Details
8/10/2017Morgan StanleyBoost Price TargetUnderweight$52.00 -> $57.00LowView Rating Details
7/21/2017Needham & Company LLCInitiated CoverageHold -> HoldLowView Rating Details
6/9/2017CowenReiterated RatingOutperform$83.00LowView Rating Details
4/26/2017Evercore ISILower Price TargetIn-Line$68.50 -> $59.00MediumView Rating Details
4/26/2017Edward JonesDowngradeBuy -> HoldHighView Rating Details
4/25/2017SunTrust BanksReiterated RatingBuyHighView Rating Details
4/25/2017Bank of AmericaReiterated RatingNeutral$77.00HighView Rating Details
3/29/2017ArgusReiterated RatingHoldLowView Rating Details
3/15/2017Wells Fargo & CompanyDowngradeMarket Perform -> UnderperformLowView Rating Details
3/8/2017Leerink SwannReiterated RatingMarket Perform$75.00LowView Rating Details
2/16/2017Credit Suisse GroupReiterated RatingBuy$85.00N/AView Rating Details
2/14/2017OppenheimerReiterated RatingHoldN/AView Rating Details
12/16/2016BarclaysReiterated RatingOverweightN/AView Rating Details
6/1/2016WedbushReiterated RatingNeutralN/AView Rating Details
5/24/2016CitigroupReiterated RatingBuyN/AView Rating Details
4/27/2016FBR & CoLower Price TargetMkt Perform$90.00 -> $75.00N/AView Rating Details
3/18/2016William BlairReiterated RatingBuyN/AView Rating Details
2/18/2016Goldman Sachs GroupLower Price TargetNeutral$82.00 -> $74.00N/AView Rating Details
12/23/2015BMO Capital MarketsBoost Price TargetMarket Perform$94.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Express Scripts (NASDAQ:ESRX) Earnings History and Estimates Chart

Earnings by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ ESRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018$2.06N/AView Earnings Details
10/24/2017Q3 2017$1.90$1.90$25.68 billion$24.68 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.71$1.73$25.52 billion$25.35 billionViewN/AView Earnings Details
4/24/2017Q1 17$1.32$1.33$24.95 billion$24.65 billionViewN/AView Earnings Details
2/14/2017Q4 2016$1.87$1.88$26.31 billion$24.90 billionViewListenView Earnings Details
10/25/2016Q3$1.74$1.74$25.48 billion$25.41 billionViewListenView Earnings Details
7/25/2016Q216$1.57$1.57$25.42 billion$25.20 billionViewListenView Earnings Details
4/25/2016Q1$1.22$1.22$25.20 billion$24.80 billionViewListenView Earnings Details
2/16/2016Q4$1.56$1.56$26.58 billion$26.18 billionViewListenView Earnings Details
10/27/2015Q315$1.44$1.45$26.38 million$25.22 millionViewListenView Earnings Details
7/28/2015Q215$1.40$1.44$26.13 billion$25.45 billionViewListenView Earnings Details
4/28/2015Q115$1.10$1.10$24.34 billion$24.90 billionViewListenView Earnings Details
2/23/2015Q414$1.38$1.39$25.68 billion$26.31 billionViewListenView Earnings Details
10/28/2014Q314$1.29$1.29$24.93 billion$25.78 billionViewListenView Earnings Details
7/29/2014Q214$1.22$1.23$24.42 billion$25.11 billionViewListenView Earnings Details
4/29/2014Q114$1.01$0.99$23.81 billion$23.69 billionViewListenView Earnings Details
2/20/2014Q413$1.12$1.12$25.49 billion$25.78 billionViewN/AView Earnings Details
10/25/2013Q313$1.08$1.08$25.01 billion$25.92 billionViewListenView Earnings Details
7/29/2013Q2 2013$1.10$1.12$25.51 billion$26.40 billionViewListenView Earnings Details
4/29/2013Q1 2013$0.97$0.99$25.55 billion$26.06 billionViewListenView Earnings Details
2/18/2013Q4 2012$1.04$1.05$27.24 billion$27.41 billionViewListenView Earnings Details
11/5/2012Q312$0.99$1.02$27.48 billion$27.00 billionViewN/AView Earnings Details
8/7/2012$0.82$0.88ViewN/AView Earnings Details
5/10/2012$0.77$0.73ViewN/AView Earnings Details
2/22/2012$0.85$0.82ViewN/AView Earnings Details
10/25/2011$0.77$0.79ViewN/AView Earnings Details
7/21/2011$0.69$0.71ViewN/AView Earnings Details
4/26/2011$0.69$0.66ViewN/AView Earnings Details
2/16/2011$0.70$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Express Scripts (NASDAQ:ESRX) Earnings Estimates

2017 EPS Consensus Estimate: $6.99
2018 EPS Consensus Estimate: $7.66
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175$1.31$1.33$1.32
Q2 20175$1.68$1.72$1.70
Q3 20175$1.90$1.91$1.90
Q4 20175$2.04$2.07$2.06
Q1 20185$1.45$1.56$1.50
Q2 20185$1.86$1.97$1.89
Q3 20185$2.02$2.06$2.04
Q4 20185$2.19$2.26$2.23
Q1 20192$1.58$1.76$1.67
Q2 20192$2.02$2.10$2.06
Q3 20191$2.25$2.25$2.25
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Express Scripts (NASDAQ:ESRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Express Scripts (NASDAQ ESRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.68%
Institutional Ownership Percentage: 88.44%
Insider Trades by Quarter for Express Scripts (NASDAQ:ESRX)
Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ ESRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017Phyllis S. AndersonVPSell643$62.37$40,103.91View SEC Filing  
10/31/2017Timothy C WentworthCEOBuy8,000$61.13$489,040.00View SEC Filing  
9/11/2017Woodrow A Myers JrDirectorSell3,900$63.93$249,327.00View SEC Filing  
9/8/2017Phyllis S AndersonVPSell578$63.13$36,489.14View SEC Filing  
8/23/2017Everett NevilleVPSell1,163$61.48$71,501.24View SEC Filing  
5/19/2017Phyllis S AndersonVPSell1,100$60.08$66,088.00View SEC Filing  
3/1/2017Everett NevilleSVPSell2,352$70.16$165,016.32View SEC Filing  
1/3/2017Everett NevilleVPSell1,123$69.41$77,947.43View SEC Filing  
9/14/2016Woodrow A Myers JrDirectorSell12,036$70.40$847,334.40View SEC Filing  
9/12/2016Christopher A McginnisVPSell1,785$70.77$126,324.45View SEC Filing  
5/10/2016Everett NevilleVPSell800$74.11$59,288.00View SEC Filing  
4/29/2016Mahon Thomas P MacDirectorSell5,482$73.93$405,284.26View SEC Filing  
3/10/2016Christopher A McginnisVPSell579$68.56$39,696.24View SEC Filing  
3/7/2016Phyllis S AndersonVPSell614$71.14$43,679.96View SEC Filing  
2/29/2016Everett NevilleVPSell4,323$71.00$306,933.00View SEC Filing  
6/9/2015Gary WimberlyVPSell1,644$87.14$143,258.16View SEC Filing  
6/1/2015Gary WimberlyVPSell46,069$86.15$3,968,844.35View SEC Filing  
3/2/2015Glen D StettinVPSell2,674$84.39$225,658.86View SEC Filing  
2/25/2015Glen D StettinVPSell27,603$87.55$2,416,642.65View SEC Filing  
12/2/2014Keith J EblingVPSell10,000$84.25$842,500.00View SEC Filing  
12/1/2014Steven B MillerVPSell4,896$83.57$409,158.72View SEC Filing  
11/28/2014Glen D StettinVPSell10,800$82.96$895,968.00View SEC Filing  
11/17/2014John O ParkerDirectorSell25,822$78.75$2,033,482.50View SEC Filing  
11/7/2014Maura C BreenDirectorSell13,128$77.80$1,021,358.40View SEC Filing  
9/5/2014Edward B IgnaczakEVPSell9,886$75.28$744,218.08View SEC Filing  
8/28/2014Seymour SternbergDirectorSell15,508$74.12$1,149,452.96View SEC Filing  
8/25/2014Keith J EblingVPSell10,000$75.50$755,000.00View SEC Filing  
8/5/2014Gary G BenanavDirectorSell12,694$70.82$898,989.08View SEC Filing  
8/5/2014Sara E WadeVPSell20,000$70.44$1,408,800.00View SEC Filing  
8/4/2014David A NortonVPSell1,276$71.02$90,621.52View SEC Filing  
8/1/2014Maura C BreenDirectorSell12,694$69.94$887,818.36View SEC Filing  
6/13/2014George PazCEOSell681,508$71.21$48,530,184.68View SEC Filing  
3/11/2014Keith EblingVPSell25,721$78.69$2,023,985.49View SEC Filing  
3/10/2014Patrick McnameeCOOSell68,425$78.28$5,356,309.00View SEC Filing  
3/10/2014Steven MillerVPSell12,664$77.96$987,285.44View SEC Filing  
3/7/2014Keith EblingVPSell295,367$77.29$22,828,915.43View SEC Filing  
1/9/2014Nicholas LahowchicDirectorSell7,650$72.00$550,800.00View SEC Filing  
12/26/2013Nicholas LahowchicDirectorSell12,694$70.00$888,580.00View SEC Filing  
11/5/2013Mahon Thomas MacDirectorSell10,251$63.20$647,863.20View SEC Filing  
9/9/2013Maura C BreenDirectorSell10,527$64.12$674,991.24View SEC Filing  
9/4/2013Woodrow Myers, Jr.DirectorSell7,128$64.66$460,896.48View SEC Filing  
7/19/2013Nicholas LahowchicDirectorSell20,377$66.26$1,350,180.02View SEC Filing  
6/11/2013Woodrow A Myers JrDirectorSell1,750$62.57$109,497.50View SEC Filing  
5/28/2013Woodrow A Myers JrDirectorSell2,000$63.75$127,500.00View SEC Filing  
5/15/2013Jeffrey HallCFOSell13,307$61.13$813,456.91View SEC Filing  
5/8/2013Woodrow A Myers JrDirectorSell13,462$61.22$824,143.64View SEC Filing  
5/1/2013Keith J EblingEVPSell59,494$59.58$3,544,652.52View SEC Filing  
4/30/2013Patrick McnameeCOOSell271,972$59.65$16,223,129.80View SEC Filing  
3/14/2013Mahon Thomas P MacDirectorBuy5,000$59.58$297,900.00View SEC Filing  
9/4/2012Jeffrey HallCFOSell75,000$62.81$4,710,750.00View SEC Filing  
8/8/2012Edward B IgnaczakEVPSell115,466$59.33$6,850,597.78View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Express Scripts (NASDAQ ESRX) News Headlines

Source:
DateHeadline
Maxim Group Increases Express Scripts (ESRX) Price Target to $87.00Maxim Group Increases Express Scripts (ESRX) Price Target to $87.00
www.americanbankingnews.com - December 14 at 4:12 PM
Express Scripts Lifts 2017 Adj. EPS ViewExpress Scripts Lifts 2017 Adj. EPS View
www.nasdaq.com - December 14 at 9:51 AM
Express Scripts forecast 2018 profit above estimates, shares riseExpress Scripts forecast 2018 profit above estimates, shares rise
finance.yahoo.com - December 14 at 9:51 AM
Express Scripts 2018 earnings forecast above estimatesExpress Scripts 2018 earnings forecast above estimates
finance.yahoo.com - December 14 at 9:51 AM
Express Scripts Will Seek Targeted Acquisitions To Bolster BusinessExpress Scripts Will Seek 'Targeted Acquisitions' To Bolster Business
finance.yahoo.com - December 14 at 9:51 AM
Express Scripts Holding Company Updates 2017 Full-Year Guidance and Announces 2018 Financial GuidanceExpress Scripts Holding Company Updates 2017 Full-Year Guidance and Announces 2018 Financial Guidance
www.prnewswire.com - December 14 at 7:52 AM
Is Express Scripts Holding Company’s (ESRX) ROE Of 23.09% Sustainable?Is Express Scripts Holding Company’s (ESRX) ROE Of 23.09% Sustainable?
finance.yahoo.com - December 9 at 5:01 PM
Lousy Industry Group Rank Keep Express Scripts (ESRX) a Sell - Investorplace.comLousy Industry Group Rank Keep Express Scripts (ESRX) a Sell - Investorplace.com
investorplace.com - December 7 at 9:59 AM
Express Scripts Outlook Improves Amid Tax Reform, CVS-Aetna Deal - BenzingaExpress Scripts Outlook Improves Amid Tax Reform, CVS-Aetna Deal - Benzinga
www.benzinga.com - December 7 at 9:59 AM
Express Scripts (ESRX) Upgraded at TheStreetExpress Scripts (ESRX) Upgraded at TheStreet
www.americanbankingnews.com - December 6 at 10:38 PM
Express Scripts (ESRX) Upgraded by Sanford C. Bernstein to Market PerformExpress Scripts (ESRX) Upgraded by Sanford C. Bernstein to Market Perform
www.americanbankingnews.com - December 6 at 8:36 AM
Express Scripts Holding Reaches Analyst Target PriceExpress Scripts Holding Reaches Analyst Target Price
www.nasdaq.com - December 5 at 10:26 AM
CVS-Aetna Deal Could Start a Health Takeover RunCVS-Aetna Deal Could Start a Health Takeover Run
finance.yahoo.com - December 5 at 10:26 AM
Moodys: CVS/Aetna merger would have negative implications for other health care companiesMoody's: CVS/Aetna merger would have negative implications for other health care companies
finance.yahoo.com - December 5 at 10:26 AM
Express Scripts (ESRX) Looks Good: Stock Adds 5.8% in SessionExpress Scripts (ESRX) Looks Good: Stock Adds 5.8% in Session
finance.yahoo.com - December 5 at 10:26 AM
Express Scripts (ESRX) Now Covered by Analysts at Deutsche BankExpress Scripts (ESRX) Now Covered by Analysts at Deutsche Bank
www.americanbankingnews.com - December 4 at 11:10 PM
Express Scripts (ESRX) Upgraded by ValuEngine to BuyExpress Scripts (ESRX) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - December 4 at 10:26 PM
No takeover for Barnes and Noble after that earnings bombNo takeover for Barnes and Noble after that earnings bomb
finance.yahoo.com - December 2 at 4:59 PM
Express Scripts Holding Company (ESRX) Receives Average Recommendation of "Hold" from AnalystsExpress Scripts Holding Company (ESRX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 1 at 5:12 PM
Adverse Earnings Momentum Make Express Scripts (ESRX) a Sell - Investorplace.comAdverse Earnings Momentum Make Express Scripts (ESRX) a Sell - Investorplace.com
investorplace.com - December 1 at 5:04 PM
Express Scripts CEO Open to Insurer Deal, Ties With AmazonExpress Scripts CEO Open to Insurer Deal, Ties With Amazon
finance.yahoo.com - November 30 at 5:04 PM
Does Express Scripts Clean Up Nicely?Does Express Scripts Clean Up Nicely?
finance.yahoo.com - November 30 at 5:04 PM
Express Scripts CEO says he sees Amazon as a potential partner -CNBCExpress Scripts CEO says he sees Amazon as a potential partner -CNBC
finance.yahoo.com - November 30 at 10:13 AM
Express Scripts CEO: Pharmacy-benefit manager model never...Express Scripts CEO: Pharmacy-benefit manager model never...
finance.yahoo.com - November 30 at 10:13 AM
Express Scripts CEO sees Amazon as a potential partner: CNBCExpress Scripts CEO sees Amazon as a potential partner: CNBC
finance.yahoo.com - November 30 at 10:13 AM
Express Scripts CEO sees Amazon as a potential pharmacy partnerExpress Scripts CEO sees Amazon as a potential pharmacy partner
finance.yahoo.com - November 30 at 10:13 AM
Zacks: Analysts Anticipate Express Scripts Holding Company (ESRX) Will Post Quarterly Sales of $24.99 BillionZacks: Analysts Anticipate Express Scripts Holding Company (ESRX) Will Post Quarterly Sales of $24.99 Billion
www.americanbankingnews.com - November 30 at 6:52 AM
Buyout Talk Intensifies As Express Scripts And Humana Shed AssetsBuyout Talk Intensifies As Express Scripts And Humana Shed Assets
finance.yahoo.com - November 29 at 9:50 AM
RALI Series 2007-QO3 Trust -- Moodys assigns B1 CFR to Diplomat Pharmacy; stable outlookRALI Series 2007-QO3 Trust -- Moody's assigns B1 CFR to Diplomat Pharmacy; stable outlook
finance.yahoo.com - November 28 at 5:08 PM
Avista Capital Partners to Acquire Express Scripts Subsidiary United BioSourceAvista Capital Partners to Acquire Express Scripts' Subsidiary United BioSource
finance.yahoo.com - November 27 at 5:53 PM
[$$] Avista to Buy Express Scripts Subsidiary[$$] Avista to Buy Express Scripts Subsidiary
finance.yahoo.com - November 27 at 5:53 PM
ETFs with exposure to Express Scripts Holding Co. : November 27, 2017ETFs with exposure to Express Scripts Holding Co. : November 27, 2017
finance.yahoo.com - November 27 at 5:53 PM
Better Buy: CVS Health Corp. vs. Express Scripts Holding CompanyBetter Buy: CVS Health Corp. vs. Express Scripts Holding Company
www.fool.com - November 22 at 8:43 AM
Bayerische Landesbank - Public-Sector Covered Bonds (10/17/2006 - 12/3/2010) -- Moodys assigns Baa2 to Express Scripts sr. notes; stable outlookBayerische Landesbank - Public-Sector Covered Bonds (10/17/2006 - 12/3/2010) -- Moody's assigns Baa2 to Express Script's sr. notes; stable outlook
finance.yahoo.com - November 20 at 7:11 PM
Express Scripts (ESRX) a Sell on Slumping Sales Growth - Investorplace.comExpress Scripts (ESRX) a Sell on Slumping Sales Growth - Investorplace.com
investorplace.com - November 16 at 2:01 PM
Propeller Health and Express Scripts Partnership Offers Innovative Digital Respiratory Care to Improve Health for People with Asthma or COPDPropeller Health and Express Scripts Partnership Offers Innovative Digital Respiratory Care to Improve Health for People with Asthma or COPD
finance.yahoo.com - November 16 at 2:01 PM
General Electric among today's IQ100 laggardsGeneral Electric among today's IQ100 laggards
finance.yahoo.com - November 14 at 6:51 PM
Neal Samples Journey From CIO To Divisional President At Amex To CIO Of Express ScriptsNeal Sample's Journey From CIO To Divisional President At Amex To CIO Of Express Scripts
finance.yahoo.com - November 13 at 6:56 PM
$24.99 Billion in Sales Expected for Express Scripts Holding Company (ESRX) This Quarter$24.99 Billion in Sales Expected for Express Scripts Holding Company (ESRX) This Quarter
www.americanbankingnews.com - November 12 at 4:46 PM
Express Scripts Holding Company Announces 2018 Financial Guidance Conference Call - PR Newswire (press release)Express Scripts Holding Company Announces 2018 Financial Guidance Conference Call - PR Newswire (press release)
www.prnewswire.com - November 11 at 6:43 PM
Express Scripts Recognized as a Best Place to Work for LGBTQ EqualityExpress Scripts Recognized as a Best Place to Work for LGBTQ Equality
finance.yahoo.com - November 10 at 1:50 PM
Express Scripts Holding Company Announces 2018 Financial Guidance Conference CallExpress Scripts Holding Company Announces 2018 Financial Guidance Conference Call
finance.yahoo.com - November 10 at 1:50 PM
Express Scripts Holding Company (ESRX) Expected to Post Earnings of $2.06 Per ShareExpress Scripts Holding Company (ESRX) Expected to Post Earnings of $2.06 Per Share
www.americanbankingnews.com - November 10 at 3:38 AM
Express Scripts Holding Co. breached its 50 day moving average in a Bullish Manner : ESRX-US : November 8, 2017Express Scripts Holding Co. breached its 50 day moving average in a Bullish Manner : ESRX-US : November 8, 2017
finance.yahoo.com - November 9 at 2:51 AM
Market Trends Toward New Normal in Public Service Enterprise Group, Rigel Pharma, National Oilwell Varco, Ironwood Pharma, Express Scripts, and Synergy Pharma – Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Public Service Enterprise Group, Rigel Pharma, National Oilwell Varco, Ironwood Pharma, Express Scripts, and Synergy Pharma – Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - November 6 at 7:57 PM
ETFs with exposure to Express Scripts Holding Co. : November 6, 2017ETFs with exposure to Express Scripts Holding Co. : November 6, 2017
finance.yahoo.com - November 6 at 7:57 PM
Express Scripts Holding Company (ESRX) Given Average Rating of "Hold" by AnalystsExpress Scripts Holding Company (ESRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 6 at 1:50 PM
Insider Selling: Express Scripts Holding Company (ESRX) VP Sells 643 Shares of StockInsider Selling: Express Scripts Holding Company (ESRX) VP Sells 643 Shares of Stock
www.americanbankingnews.com - November 3 at 6:50 PM
Five Companies on Amazons List to Buy - Investopedia (blog)Five Companies on Amazon's List to Buy - Investopedia (blog)
www.investopedia.com - November 3 at 6:03 PM
Health care CEOs raise the specter of AmazonHealth care CEOs raise the specter of Amazon
finance.yahoo.com - November 3 at 6:03 PM

SEC Filings

Express Scripts (NASDAQ:ESRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Express Scripts (NASDAQ:ESRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Express Scripts (NASDAQ ESRX) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.